Gilead Sciences has entered a significant partnership to develop cancer treatments.
Gilead Sciences Inc (GILD.US) announced a new collaboration with Vir Biotechnology focused on developing novel therapies for solid tumors. This partnership is expected to enhance Gilead's oncology pipeline with innovative treatments, potentially leading to significant advancements in cancer care. Following the announcement, Gilead's stock closed at US$153.54, reflecting a 3.80% increase in one day, with year-to-date gains of 28.54%.
Investor takeaway: Investors should monitor the developments from this partnership as it may impact Gilead's future growth prospects.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$190.38B
Div. yield
2.18%
Div. / share
$3.22
52W high
$160.51
52W low
$111.27
1W change
+6.98%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 16, 2026
Wall Street analysts forecast GILD stock price to rise 403.2% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.58
+403.2% Upside
Previously C$159.62 on Oct 14, 2026
Current Price
C$31.71
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
23.9%
Annualized
90-Day Vol
28.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$188.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$167.02 | C$153.78 – C$181.41 |
| 60 trading days | C$177.27 | C$157.72 – C$199.24 |
| 90 trading days | C$188.14 | C$163.05 – C$217.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Gilead's stock rose 3.80% following the partnership announcement.
The latest trading volume was 5,692,108 shares, slightly below the 20-day average of 5,924,043 shares.
Bull case
This partnership could speed up Gilead's entry into the solid tumor market, improving its product lineup and revenue potential.
Bear case
The financial implications of this partnership are still unclear, and Gilead faces existing challenges, such as negative profit margins, which could affect investor sentiment.
Gilead Partners with Vir Biotechnology
Advertisement
Gilead Sciences has formed a multi-program collaboration and licensing agreement with Vir Biotechnology to develop PRO-XTEN® Dual-masked T-cell engagers aimed at treating solid tumors. This partnership is significant as it allows Gilead to expand its oncology offerings, which have been a focus area for growth amid increasing competition in the biopharmaceutical sector. The development comes at a time when Gilead is looking to enhance its product portfolio in the oncology space.
Stock Performance Following the Announcement
Gilead's stock closed at US$153.54, reflecting a 3.80% increase on the news of the partnership. The stock has shown strong performance over the past month, with a 5.46% increase, and has gained 4.56% over the past week. The latest trading volume was 5,692,108 shares, slightly below the 20-day average of 5,924,043 shares. Gilead's stock is currently trading at 5.8% above its 50-day moving average of US$145.12 and 11.7% above its 200-day moving average of US$137.44.
Future Implications of the Partnership
As Gilead moves forward with this collaboration, investors will be watching for updates on the progress of the dual-masked T-cell engagers in clinical trials. The partnership's success could significantly influence Gilead's market position in oncology and its overall financial health, especially given its current profit margin challenges of -10.6% and a negative return on equity of -20.7%. Analysts have set an average target price of US$159.62 for Gilead's stock, implying a potential upside of 4.0% from the current levels.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
